Immunotherapy for Prostate Cancer Could Have Spectacular Results

Adjust Comment Print

Data from some other cancer types, such as bowel, has similarly shown tumours with defects in DNA fix mutations are more susceptible to immunotherapy.

"It's thrilling that immunotherapy might supply some males extra time with their family members the place they've such superior illness that they've run out of present therapy choices".

Drugs that boost the immune system have saved the lives of some men with terminal prostate cancer, say doctors in the UK.

General, survival is sweet for the most cancers, with 84 per cent nonetheless alive 10 years after first analysis.

Eleni Efstathiou, MD, and colleagues at The University of Texas MD Anderson Cancer Center in Houston, studied 197 patients with M0HNPC randomly assigned to receive AA plus leuprolide (99 men) for 8 months or leuprolide alone (98 men).

Earlier studies found that black men with advanced prostate cancer who received treatment died sooner than white men, but the evidence has been inconsistent, the researchers noted.

Two years ago, he was given the immunotherapy drug pembrolizumab. We have several patients in the Marsden who have had a complete response.

Your immune system is trained to fight infection, but it also attacks parts of the body if they malfunction - such as in cancers. Prostate cancer is treated in a number of ways, but the more extreme treatments which include surgical interventions may cause physical and psychological side effects. The latest trial, results of which were presented this weekend at the American Society of Clinical Oncology Meeting in Chicago, examined the genetics of tumors and found that certain groups of prostate cancer patients may benefit from the treatment. Prostate cancer can develop when cells in the prostate start to grow in an uncontrolled way.

Professor de Bono said: "We are planning a new clinical trial, specifically in men with prostate cancer whose tumours have mutations in DNA fix genes, to see if immunotherapy can become a standard part of their treatment".

"One of the major challenges with immunotherapy is that we don't have many reliable tests to pick out who will benefit", added Professor Paul Workman, chief executive of The ICR.

"In the last few years immunotherapy has changed the way we treat many advanced cancers - but up to now no one had demonstrated a benefit in men with prostate cancer".

That is not a given, as a course of treatment in other cancers typically costs tens of thousands of pounds per patient.

"This study underscores the importance of increasing the participation of racial minorities in clinical trials".

The tests picked up nearly 90 per cent of late-stage cancers.

Professor Geoffrey Oxnard, of the Dana-Farber Cancer Institute in the U.S., said: 'The beauty of a blood test is it could just be done in a local GP office'.